Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesDental/Oral & MaxillofacialAetna distraction osteogenesis Coverage Update | O…
    Ask Trek AI about this page
    CurrentAetnaPolicy 0549

    Distraction Osteogenesis for Craniofacial Defects

    Customize your policy alerts

    Sign up for Aetna Policy 0549 alerts

    Get alerted when Policy 0549 changes without checking for updates manually.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    This policy governs when Aetna considers distraction osteogenesis medically necessary or experimental/investigational for treatment of congenital craniofacial skeletal deformities and related indications, and lists coding and policy limitations relevant to providers and members.

    Policy Summary
    PayerAetna
    PolicyDistraction Osteogenesis for Craniofacial Defects
    Policy CodePolicy 0549
    Change TypeNo material changes
    Effective DateAug 14, 2001
    Last ReviewAug 9, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain prior authorization and document that the patient meets one of the listed medically necessary congenital indications.
    SourceLink

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    8specific congenital indications listed as medically necessary
    >=10 mmmandibular lengthening threshold
    89.3%airway success rate (pooled)
    23.8%overall complication rate (pooled)

    Coverage Criteria for Distraction Osteogenesis

    inv-01: Medically necessary congenital indications

    Aetna considers distraction osteogenesis medically necessary for the correction of functional impairments when ANY one of the following congenital craniofacial conditions is present:

    Medically necessary indications: 1. Cleft lip and palate; OR 2. Correction of hemifacial microsomia in children with sufficient bone to allow corticotomy/osteotomy and placement of pins for external or internal distraction devices (Pruzansky Grade I and IIa mandibular deformity); OR 3. Severe congenital mandibular deficiency requiring lengthening of the mandible > 10 mm (orthognathic surgery can correct smaller deformities); OR 4. Severe micrognathia (eg, Pierre Robin sequence or Treacher Collins syndrome) in infants and children with airway obstruction; OR 5. Lengthening of a short mandibular ramus (stretching of the pterygomasseteric sling); OR 6. Non-syndromic craniosynostosis — coronal (bilateral or unilateral) or sagittal; OR 7. Syndromic craniosynostosis — Apert, Crouzon, or Pfeiffer syndromes; OR 8. Widening of a narrow mandible or maxilla.

    Upon review by Aetna's Oral and Maxillofacial Surgery (OMS) Unit, distraction osteogenesis may be considered medically necessary for other congenital anomalies when distraction osteogenesis can uniquely produce improvement unavailable with other standard techniques.

    inv-02: Experimental/investigational (not established)

    The following are considered experimental and investigational for Aetna and are therefore not covered:

    Experimental: 1. Distraction osteogenesis for acquired craniofacial defects (e.g., reconstruction following tumor resection or ablative head and neck surgery), for obstructive sleep apnea, and for other craniofacial indications due to insufficient evidence regarding clinical value; OR 2. Enhancement of bone formation during distraction osteogenesis by means of bone morphogenetic proteins or local injection of bone marrow aspirate and platelet gel because effectiveness has not been established.

    Distraction osteogenesis performed solely for cosmetic purposes is excluded (not covered).

    inv-03: Evidence-based coverage considerations

    Evidence summaries and contextual findings from cited reviews and studies:

    Evidence summaries: Pluijmers et al. (2014): In unilateral craniofacial microsomia, mandibular corrective outcomes are more dependent on patient/deformity grade than on treatment choice; best results seen in Pruzansky-Kaban type I and IIa. Single-stage asymmetry correction should generally be postponed until permanent dentition; severely hypoplastic mandibles may benefit from a multi-stage approach for functional or psychosocial reasons.
    Airway outcomes: Tahiri et al. (2014): In a pooled review of 74 studies (711 pediatric patients, mean age ~18.1 months), mandibular distraction osteogenesis successfully treated airway obstruction in 89.3% of cases (success defined as decannulation, avoidance of tracheostomy/CPAP, or marked OSA improvement); 84.2% (171/203) of tracheostomy-dependent patients were decannulated and 95.6% (of 181 patients with OSA) had complete resolution or significant improvement. An overall complication rate of 23.8% was reported.
    Adjuncts to enhance bone formation: Sabharwal (2011) and Terbish et al. (2015): Various mechanical and adjunctive modalities (eg, altered distraction protocols, low-intensity pulsed ultrasound, pulsed electromagnetic fields) have been proposed to enhance regenerate. Animal data (rhBMP-2 in a canine alveolar DO model) showed increased bone volume, width, and density after consolidation, but these findings require evaluation in human studies; clinical evidence remains insufficient to establish routine use of BMPs or local bone marrow/platelet gel in DO.

    Aetna considers distraction osteogenesis (DO) for acquired craniofacial defects, for obstructive sleep apnea (OSA), and for all other craniofacial indications not specifically listed as medically necessary to be experimental and investigational because of insufficient evidence regarding clinical value for these indications. Coverage for these uses is not provided under this policy.

    Distraction osteogenesis performed solely to improve appearance or facial profile (cosmetic purposes) is excluded from coverage. Such procedures are considered cosmetic and are not eligible for medical coverage under this policy.

    Distraction osteogenesis performed in preparation for dental implants or orthodontic care is not covered when the member’s benefit plan excludes dental implants or orthodontic services. Providers should check the member’s benefit plan description to determine whether these dental services are excluded prior to submitting authorization requests.

    This policy excerpt does not list additional, explicit exclusion conditions beyond those stated (acquired defects, OSA, cosmetic purposes, and DO related to excluded dental/orthodontic coverage). The absence of other named exclusions in this portion of the document does not override plan-specific benefit limitations or other related CPBs referenced in the policy.

    Certain procedure and supply codes associated with augmentation or adjunct biologic products are constrained by the policy: for example, CPT codes 0232T and 0481T and HCPCS code S9055 are identified in the policy context as related to injections or growth-factor preparations and are considered not covered for indications listed as experimental or cosmetic in this CPB. Providers should reference the coding section and plan benefits when submitting claims for these services.

    Within the extract provided there are no discrete ‘not medically necessary’ criteria detailed; the document instead designates certain indications as experimental/investigational or cosmetic exclusions and references plan benefit limits. Administrative items such as review dates and policy history are listed separately.

    Coding — CPT, HCPCS, and ICD-10

    CPT codes covered if selection criteria are metCPTCovered
    20692Application of multiplane (pins or wires in more than one plane), unilateral, external fixation system (eg, Ilizarov, Monticelli type).
    20693Adjustment or revision of external fixation system requiring anesthesia (eg, new pin(s) or wire(s) and/or new ring(s) or bar(s)).
    20694Removal, under anesthesia, of external fixation system.
    20696Application of multiplane (pins or wires in more than one plane), unilateral, external fixation with stereotactic computer-assisted adjustment (eg, spatial frame), including imaging; initial and subsequent alignment(s), assessment(s), and computation(s) of adjustment schedule(s).
    20697Exchange (ie, removal and replacement) of strut, each.
    CPT codes not covered for indications listed in the CPBCPTNot Covered
    0232TInjection(s), platelet rich plasma, any site, including image guidance, harvesting and preparation when performed.
    0481TInjection(s), autologous white blood cell concentrate (autologous protein solution), any site, including image guidance, harvesting and preparation, when performed.
    Other CPT codes related to the CPBCPT
    20939Bone marrow aspiration for bone grafting, spine surgery only, through separate skin or fascial incision (List separately in addition to code for primary procedure).
    21110Application of interdental fixation device for conditions other than fracture or dislocation, includes removal.
    21120-21196Repair, revision, and/or reconstruction bones of face.
    21206Osteotomy, maxilla, segmental (e.g., Wassmund or Schuchard).
    21210Graft, bone; nasal, maxillary or malar areas (includes obtaining graft).
    21247Reconstruction of mandibular condyle with bone and cartilage autografts (includes obtaining grafts) (eg, for hemifacial microsomia).
    30400-30462Rhinoplasty.
    42200-42225Palatoplasty.
    HCPCS codes not covered for indications listed in the CPBHCPCSNot Covered
    S9055Procuren or other growth factor preparation to promote wound healing.
    Other HCPCS/dental codes related to the CPBmixed
    D6010-D6199Implant services.
    D7946-D7949LeFort procedures I, II, or III.
    D8010-D8999Orthodontic dental procedures.
    ICD-10 codes (covered and not covered as noted)ICD-10
    M26.00-M26.59Dentofacial anomalies [including malocclusion].
    Q35.1-Q35.9Cleft palate.
    Q37.0-Q37.9Cleft palate with cleft lip.
    Q67.0-Q67.4Congenital deformities of skull, face and jaw.
    Q75.0-Q75.9Congenital malformation of skull and face bones [includes hemifacial microstomia].
    Q87.0Congenital malformation syndromes predominantly affecting facial appearance.
    G47.33Obstructive sleep apnea (adult) (pediatric).
    M95.2Other acquired deformity of head [acquired craniofacial defects].
    Z41.1Encounter for cosmetic surgery.
    Z46.3Encounter for fitting and adjustment of dental prosthetic device.
    1–10 of 11
    1/2
    Mandibular advancement magnitude — when distraction is indicated
    Threshold> 10 mm advancement of the mandible
    RationaleConventional orthognathic procedures become more difficult and less predictable when greater than 8 to 10 mm advancement is needed; growth modification via orthodontics generally produces no more than 5 mm differential growth.
    Policy implicationWhen mandibular lengthening >10 mm is required, distraction osteogenesis is indicated over single‑stage orthognathic advancement.

    Provider Obligations, Prior Authorization, and Documentation

    Prior Authorization

    Prior Authorization and Coverage Contingency

    Prior authorization: Not specified in the extracted policy text. Providers should verify plan-specific prior authorization requirements before scheduling distraction osteogenesis, as coverage may be contingent on meeting Aetna medical necessity criteria and plan benefits.

    • Coverage is contingent on meeting the medical necessity criteria listed in this policy (see Medical Necessity section).
    • When treating congenital anomalies not explicitly listed, document review by Aetna's Oral and Maxillofacial Surgery (OMS) Unit may be required.
    • Check the member's benefit plan for exclusions related to dental implants or orthodontic care; DO is not covered when such procedures are excluded.
    Documentation Required

    Support Indication and Coding

    Documentation must support one of the listed congenital indications and include relevant clinical details, operative reports, and applicable diagnosis/procedure codes.

    Background on Distraction Osteogenesis

    Distraction osteogenesis is a surgical technique that lengthens and reshapes bone by performing an osteotomy followed by gradual mechanical separation of the bony segments using internal or external devices. The process typically advances bone at approximately 1–2 mm per day until the desired length is reached, with hardware retained during a consolidation period (commonly several weeks) to allow new bone formation and stability.

    Definitions

    Distraction osteogenesis — technique and mechanism
    DefinitionSurgical technique that lengthens and reshapes bone by performing an osteotomy and gradually separating bony segments with internal or external fabricated hardware to produce new bone formation in the gap.
    MechanismAfter surgical fracture, fragments are held for about one week to allow callus formation, then distracted typically at 1–2 mm per day until the predetermined length is reached; hardware is left in place for approximately 6 additional weeks until calcification/consolidation.
    DevicesSpecially fabricated internal or external distractor devices; external devices allow multi‑dimensional control but are more conspicuous and prone to traction scars; internal devices are less visible but uni‑directional and require removal surgery.
    Orthognathic surgery — definition and fixation
    DefinitionSurgical correction of skeletal anomalies of the midface, mandible and maxilla that involves osteotomy and repositioning of bony segments with fixation (eg, plates, screws, wires).
    Policy Summary
    PayerAetna
    PolicyDistraction Osteogenesis for Craniofacial Defects
    Policy CodePolicy 0549
    Change TypeNo material changes
    Effective DateAug 14, 2001
    Last ReviewAug 9, 2023
    Next Review DateJun 13, 2024
    Key ActionObtain prior authorization and document that the patient meets one of the listed medically necessary congenital indications.
    SourceLink
    On This Page
    Coverage Criteria for Distraction OsteogenesisCoding — CPT, HCPCS, and ICD-10Provider Obligations, Prior Authorization, and DocumentationBackground on Distraction OsteogenesisDefinitions
    Irradiated skeleton considerations: Momeni et al. (2017): Systematic review of DO in the irradiated craniofacial skeleton (38 patients) found a 50% overall complication rate with insufficient bone formation the most common complication (9 patients, ~23%); complication incidence was not significantly associated with radiation dose. Authors concluded DO can be offered to selected irradiated patients, acknowledging elevated risks.
    • Include clinical summary stating the specific congenital diagnosis (e.g., cleft lip/palate, Pruzansky Grade I/IIa hemifacial microsomia, severe mandibular deficiency >10 mm, Pierre Robin sequence with airway obstruction, syndromic/non-syndromic craniosynostosis).
    • Provide objective findings demonstrating functional impairment (e.g., airway obstruction, feeding or speech impairment) and measurements supporting need for lengthening (e.g., anticipated millimeters of distraction).
    • Attach relevant pre- and post-operative imaging, surgical plan (corticotomy/osteotomy details), and expected distraction protocol.
    • List and bill with appropriate CPT/HCPCS/ICD-10 codes as supported by documentation (see codes section).
    Documentation Required

    Consideration of Conventional Alternatives

    Consideration of conventional alternatives: Providers should document why standard surgical techniques (for example, orthognathic surgery or staged grafting/osteotomy) are not expected to achieve the required functional improvement or magnitude of correction.

    • Distraction osteogenesis is generally indicated when the deformity magnitude (e.g., mandibular lengthening >10 mm) or anatomy makes conventional orthognathic approaches inadequate.
    • For hemifacial microsomia, indicate Pruzansky grade and why distraction is preferred over single-stage correction or grafting.
    • When other congenital anomalies are treated, document OMS Unit review and rationale that DO can uniquely produce improvement unavailable with standard techniques.
    Denial Risk

    Experimental/Investigational and Cosmetic Exclusions (Denial Risk)

    Experimental, cosmetic, and excluded uses: The policy lists specific scenarios that are not covered or considered experimental; documenting attempts at alternatives will not make these indications payable.

    • Distraction osteogenesis for acquired craniofacial defects (e.g., post-tumor resection), obstructive sleep apnea, and other non-congenital craniofacial indications is considered experimental/investigational and not covered.
    • Use of bone morphogenetic proteins (BMPs), local bone marrow aspirate, or platelet gel at the osteotomy site during DO is experimental/investigational.
    • DO performed solely for cosmetic improvement is excluded from coverage and may be denied.
    • Ensure benefit plan exclusions for dental implants or orthodontic care are checked, as DO is not covered under plans that exclude those services.
    Fixation and adjunctsBones are generally held in their new positions with plates, screws and wires; arch bars (intermaxillary fixation) may be used for added stability; bone grafting or alloplastic replacement may be required when deficient bone tissue is present.
    Indications (examples)Mandibular prognathism, mandibular retrognathia, maxillary excess, maxillary deficiency, and apertognathia (open bite deformity).
    Success (airway) — definition per Tahiri et al. (2014)
    Tahiri et al. (2014) definition of successDe‑cannulation of tracheostomy, avoidance of tracheostomy or continuous positive airway pressure (CPAP), or alleviation/significant improvement of obstructive sleep apnea (OSA) symptoms.
    Reported success rateMandibular distraction osteogenesis successfully treated airway obstruction in 89.3% of pooled pediatric cases (711 patients).
    Supporting outcomesOf 203 tracheostomy‑dependent patients, 171 (84.2%) were de‑cannulated; among 181 patients with OSA, 95.6% had complete resolution or significant improvement.